Recently, Accenture (Accenture Inc.) Made a strategic investment in Earli through Accenture Ventures.Earli has developed a novel early cancer detection method, known as ”synthetic liquid biopsy” technology, which can use genetic components to induce cancer cells to produce biomarkers that are not normally expressed in the human body, and then locate early cancer lesions.
This investment by Accenture Ventures will support the expansion of Earli’s cooperation with global health and pharmaceutical companies that can use Earli’s technology to detect and treat cancer faster and more accurately.
Earli’s core technology originated from Stanford University. Unlike the current mainstream early detection methods that rely on markers naturally released by cancer cells, the “synthetic liquid biopsy” technique uses injection of a synthetic complex into the human body. This substance will randomly spread to healthy cells and cancer cells (if any).If a cancer cell is encountered, it will force the cancer cell to express a “synthetic liquid biopsy” substance that the normal human body will not express, so that the cancer cell can be detected by a PET scan.
Earli’s scientific advisory board has a luxurious lineup, including two Nobel Prize winners: Jim Allison, the 2018 Nobel Laureate in Physiology or Medicine and director of immunology at MD Anderson Cancer Center; Lee Hartwell, the 2001 Nobel Laureate in Physiology or Medicine; and Bob Langer, a professor at MIT and co-founder of Moderna, and many other academic bigwigs.
Dr. Petra Jantzer, senior managing director and global head of Accenture’s life sciences business, said: “Earli’s synthetic biopsy method is a step change in early cancer detection technology and will provide biopharmaceutical companies with significant advantages by improving the accuracy and effectiveness of new therapies and diagnostics, as well as understanding the mechanisms of cancer progress.”
“Accenture’s impressive network of biopharmaceutical customers will have a very big impact on Earli.Accenture supports our mission to make cancer a benign experience, which is great.“Earli Inc.Co-founder and CEO Cyriac Roeding said.
Tom Lounibos, global head of Accenture Venture Capital, said: “Earli’s technology is based on decades of biological data that analyzes a variety of factors and identifies specific proteins that lead to cancer development, thereby improving the effectiveness and reliability of the synthetic biopsy process.With Earli joining our Project Spotlight program, we can work with customers in the biopharmaceutical industry to improve their capabilities in cancer research, drug development, and patient care.”
